Introduction
============

Chronic obstructive pulmonary disease (COPD) causes significant morbidity and mortality worldwide in the elderly and is estimated to become the third highest cause of death globally by 2020.[@b1-copd-13-1309],[@b2-copd-13-1309] The mortality trend of patients with COPD in Taiwan has increased since 2009 in both genders, but especially in males.[@b3-copd-13-1309] The COPD age-adjusted mortality of males increased from 51.89 to 59.67 per 100,000 persons from 2010 to 2012.[@b3-copd-13-1309] Good disease and symptom control in patients with COPD can improve the health-related quality of life and reduce the national economic burden.

Respiratory inhalers are commonly used to deliver long-acting bronchodilators to control symptoms and prevent exacerbations in patients with COPD.[@b4-copd-13-1309] Moreover, respiratory inhalers provide the advantage of targeted drug delivery to the airways, which can reduce the occurrence of systemic adverse reactions. Previous studies have shown that 4%--94% of patients use their inhalers inappropriately.[@b5-copd-13-1309],[@b6-copd-13-1309] Poor inhaler technique may decrease the dosage of medicines and affect symptom management.[@b7-copd-13-1309],[@b8-copd-13-1309] Risk factors for inhaler misuse include older age,[@b9-copd-13-1309] the use of multiple inhalers,[@b10-copd-13-1309] and low health literacy.[@b11-copd-13-1309] However, the rate and risk factors of inhaler misuse in Taiwanese patients with COPD is unclear. Therefore, this baseline examination may help to establish strategies to improve inhaler therapy.

Previously, we found that patients with COPD and osteoporosis had worse health-related quality of life.[@b12-copd-13-1309] In this study, we enrolled outpatients with COPD who were referred to the chest clinic of a community hospital and evaluated their inhaler techniques and the patient characteristics associated with incorrect inhaler techniques.

Material and methods
====================

Study participants and design
-----------------------------

This study was conducted between January 2013 and October 2014 at the outpatient department of the Division of Pulmonary and Critical Care Medicine, Ditmanson Medical Foundation Chia-Yi Christian Hospital, which is a 1,000-bed community-based teaching hospital in Chiayi, Taiwan. Potential participants were male and female outpatients with a diagnosis of COPD and ≥40 years old. The potential participants were required to meet the inclusion and exclusion criteria. Patients who met the screening criteria and agreed to sign the informed consent form became study participants. The inclusion criterion was the use of at least one inhaler device. Exclusion criteria included a diagnosis of dementia or a history of bronchial asthma or other structural lung diseases (ie, lung cancer, bronchiectasis, or fibrotic lung).[@b12-copd-13-1309] This cross-sectional study was approved by the Institutional Review Board of the Ditmanson Medical Foundation Chia-Yi Christian Hospital, Taiwan.

Checklists used to assess correct inhaler technique
---------------------------------------------------

The inhaler technique was evaluated by using detailed checklists. The checklists for each of the five inhaler types were developed according to the manufacturers' recommendations and reports in the published literature.[@b13-copd-13-1309]--[@b15-copd-13-1309] The five inhaler types were: 1) a metered-dose inhaler (MDI) with spacer: Alvesco (3M Health Care Limited, Loughborough, Leicestershire, UK), Foster (Chiesi Farmaceutici S.p.A, Parma, Emilia-Romagna, Italy), and Seretide evohaler (Glaxo Wellcome Production, Évreux, Normandy, France); 2) Diskus^®^: Seretide accuhaler (Glaxo Wellcome Production, Évreux, Normandy, France); 3) Turbuhaler^®^: Symbicort (AstraZeneca AB, Södertälje, Södermanland, Sweden); 4) Respimat^®^: Spiriva (Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim am Rhein, Rhineland-Palatinate, Germany); and 5) Breezhaler^®^: Onbrez (Novartis Pharma Stein AG, Stein, Aargau, Switzerland). Using a spacer can help patients to easily seal their lips and inhale the drug. The eight steps of inhaler use that we evaluated were: 1) assemble the inhaler; 2) hold the inhaler correctly; 3) breathe out fully; 4) seal lips around the mouthpiece; 5) press down the inhaler; 6) press for the number of puffs specified; 7) inhalation timing; and 8) hold breath. A well-trained case manager was assigned to evaluate the step-by-step accuracy of inhaler use. When examining the inhaler technique, misuse of an individual inhaler was defined as an error in at least one step.

Study parameters
----------------

Sociodemographic characteristics, including the patient's age, gender, education level, type and number of inhalers, and inhaler-related knowledge, were recorded using questionnaires. Inhaler-related knowledge included three items: the inhaler dosage; the time period during which the inhaler could be used; and washing the mouth to prevent ulceration, which was based on the instructions from the manufacturer of each inhaler. Incorrect inhaler-related knowledge was defined as the occurrence of an error in any one of the three items. Hearing ability and vision were classified into two subgroups (good and poor). The poor vision subgroup included patients who needed the case manager to read the questionnaires and write down the answers. Patients with good vision could read the questionnaires and answer independently. The font size used in the questionnaire was 14. Poor hearing ability was defined as a patient needing the case manager to speak loudly during conversation. The number of acute exacerbations in the preceding 3 months was reviewed from the medical records of the individuals. The definition of acute exacerbation was a change in the regular medication of patients who visited the outpatient clinic or referral for hospitalization.[@b16-copd-13-1309]

Statistical analysis
--------------------

Differences in patient characteristics between the pass and misuse groups for the different inhalers was tested using the Student's *t*-test and chi-square test. The crude and adjusted odds ratio (OR) and 95% confidence intervals (CIs) were calculated using a logistic regression model to investigate the associations of the patient characteristics with incorrect inhaler use. All of the analyses were conducted using SPSS software, version 21, of the SPSS System for Windows (IBM Corporation, Somers, NY, USA). Statistical significance was set at a two-tailed *p*-value \<0.05.

Results
=======

Patient demographics
--------------------

We enrolled 298 patients in this study ([Table 1](#t1-copd-13-1309){ref-type="table"}). The mean age of the patients was 72.10 years. A majority of the patients were male (284, 95.30%) and had education levels of less than junior high school (212, 71.14%). The numbers of patients using MDI with spacer, Diskus, Turbuhaler, Respimat, and Breezhaler were 79 (26.51%), 20 (6.71%), 21 (7.05%), 223 (74.83%), and 100 (33.56%), respectively. Additionally, 45.30% of the patients used two or more inhalers. The average time duration the patients had used their inhalers was 9.91±13.68 months.

Misuse rates for respiratory inhalers
-------------------------------------

The misuse rates for the five different types of inhalers ranged from 65.00% (Breezhaler) to 87.89% (Respimat). No significant differences were found in age, gender, body mass index (BMI), education level, and vision between the pass and misuse groups for the five inhaler types ([Table 2](#t2-copd-13-1309){ref-type="table"}). Patients with poor hearing were more likely to use the MDI with spacer incorrectly. Higher proportions of patients in the misuse groups for the MDI with spacer, Turbuhaler, Respimat, and Breezhaler consistently presented incorrect inhaler-related knowledge as compared to the proportions of patients in the pass groups (*p*\<0.05).

The correct and incorrect frequencies for each step of the five inhalers are presented in [Table 3](#t3-copd-13-1309){ref-type="table"}. The incorrect rate for the step "assemble the inhaler" was especially high in patients using Respimat (62.78%), compared to patients using the other inhalers (0.00%--18.99%). Across all of the inhaler types, the step most likely to be performed incorrectly was "breathing out fully" (58.00%--80.95%). Further, the step "holding breath" showed a relatively high rate of error among patients using the five types of inhalers (29.00%--47.62%). For the other steps, the frequency of incorrect performance ranged from 0.00% to 22.78% of the patients.

Patient characteristics related to misuse of inhalers
-----------------------------------------------------

Age, gender, BMI, education level, and vision were not related to misuse across the five types of inhalers ([Table 4](#t4-copd-13-1309){ref-type="table"}). However, incorrect inhaler-related knowledge was significantly associated with patients misusing three inhalers: the MDI with spacer (adjusted odds ratio \[aOR\] 9.58; 95% CI 2.14--42.80), Respimat (aOR 5.14; 95% CI 2.07--12.76), and Breezhaler (aOR 6.98; 95% CI 1.95--25.08). When handling the MDI with spacer, patients with poor hearing exhibited increased misuse as compared with patients with good hearing (aOR 9.85; 95% CI 1.40--69.30). Additionally, misuse in handling the Breezhaler increased the number of acute exacerbations (aOR 4.07; 95% CI 1.50--11.08).

Discussion
==========

A national epidemiological survey of patients with COPD in Taiwan revealed that patients with COPD defined by a clinical diagnosis were mostly \>50 years.[@b17-copd-13-1309] In the present study, the 298 patients with COPD enrolled from a regional hospital had an average age of 72.10 years. The high misuse rates of the five inhalers ranged from 65.00% to 87.89%. The Respimat inhaler was more likely to be assembled incorrectly than the other inhalers. Across all of the inhalers, the steps that were most likely to be performed incorrectly were "breathing out fully" and "holding breath." Incorrect inhaler-related knowledge was significantly associated with misuse of the MDI with spacer, Respimat, and Breezhaler.

The incidence of COPD increases with age, and COPD is more common in men than in women.[@b18-copd-13-1309] Additionally, risk factors for incorrect inhaler techniques include older age.[@b9-copd-13-1309] However, there are inconsistent results with regard to whether age is related to the incorrect use of inhalers.[@b9-copd-13-1309],[@b19-copd-13-1309],[@b20-copd-13-1309] Öztürk et al[@b20-copd-13-1309] demonstrated that handling errors were especially common in the older group (≥65 years). The mean age of the patients enrolled in the current study was 72.10±8.98 years, and age was not associated with incorrect inhaler techniques ([Tables 2](#t2-copd-13-1309){ref-type="table"} and [4](#t4-copd-13-1309){ref-type="table"}). Because the dominant population of patients (65.10%) was ≥70 years and the age distributions between the pass and misuse groups were similar, the age effect might not be critical in participants ≥70 years.

Previous studies demonstrated that the proportion of patients who used the MDI incorrectly was higher than the proportions of patients using other inhalers.[@b21-copd-13-1309],[@b22-copd-13-1309] Moreover, a study by Ganguly et al showed that the higher proportion of users of MDI with spacer handle the device correctly (20.80%), compared with MDI users (6.00%) and dry power inhaler (DPI) users (16.12%).[@b23-copd-13-1309] However, those studies did not include Respimat. Our study included Respimat, and found that its misuse rate was highest (87.89%) across the five inhaler types ([Table 2](#t2-copd-13-1309){ref-type="table"}). Similarly, Molimard et al[@b24-copd-13-1309] demonstrated that the handling error with Respimat was higher than in the other four inhalers. Moreover, the incorrect rate in the "assemble the inhaler" step was particularly high when Respimat was used (62.78%, [Table 3](#t3-copd-13-1309){ref-type="table"}). These results indicate that Respimat is an inhaler whose use needs to be carefully learned -- especially the step of assembling the inhaler. Health education providers should help patients confirm the accuracy of this step for Respimat. Additionally, our study found that the step "breathe out fully" had the most errors across all types of inhalers. Lee et al[@b19-copd-13-1309] evaluated the inhaler techniques of patients with COPD in South Korea with similar age (66.8±8.2) and gender distributions (male: 91.8%) to that of the study population in the present study. Their results also demonstrated that the highest incorrect frequency occurred in the "breathe out fully" step. Failing to perform this step correctly decreased the patient's ability to take a full breath and affected the delivery of the inhaled medication. Additionally, a relatively high rate of errors occurred in the step "hold breath" in the study, which was consistent with the results of the previous study.[@b8-copd-13-1309]

A lower education level did not increase the misuse rate of handling inhalers in the present study, which was in agreement with the findings of the study by Lee et al.[@b19-copd-13-1309] Melani et al[@b8-copd-13-1309] revealed that errors in the critical steps were reduced in patients with a higher degree of education, but that study included patients with COPD as well as those with asthma. Therefore, whether the characteristics of patients with asthma influenced the results is unclear. Our findings showed that poor vision was not significantly associated with incorrect inhaler techniques ([Tables 2](#t2-copd-13-1309){ref-type="table"} and [4](#t4-copd-13-1309){ref-type="table"}). However, a previous study found that poor vision was associated with Diskus misuse but it did not find significant associations between poor vision and MDI misuse.[@b5-copd-13-1309] The authors described other device-specific unmeasured confounders that might be responsible for incorrect inhaler techniques and may need to be evaluated further. Moreover, we found that poor hearing and the number of acute exacerbations were specifically related to misuse of the MDI with spacer and Breezhaler ([Table 4](#t4-copd-13-1309){ref-type="table"}), respectively. Thus, other device-specific factors could have influenced these results.

Incorrect inhaler-related knowledge significantly increased the possibilities of misuse of the MDI with spacer, Respimat, and Breezhaler ([Table 4](#t4-copd-13-1309){ref-type="table"}). This finding emphasizes the importance of patients' inhaler-related knowledge. Therefore, health education providers should provide professional information about the various types of inhalers and confirm patients' knowledge about their inhalers.

This study has some limitations. The sample size of patients handling the Diskus and Turbuhaler inhalers was small. Therefore, large-scale studies are needed to verify the results. Moreover, neither well-trained health education providers nor standardized educational guidelines were available to undertake the inhaler education, which could have led to inhaler misuse by the patients. Therefore, health education providers should be trained to be professional and responsible when applying standardized patient education guidelines. Despite these limitations, this study provides the first data regarding the misuse of different types of inhalers in Taiwan.

Conclusion
==========

These data provide an overview of inhaler misuse and are helpful in devising a strategy to decrease inhaler use errors. Based on the current study, educational interventions should be designed to correct individual errors in inhaler technique.
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###### 

Demographic characteristics of patients (N=298)

                                                N            \%
  --------------------------------------------- ------------ -------
  Age, years (mean ± SD)                        72.10±8.98   
   \<60                                         22           7.38
   60--69                                       82           27.52
   ≥70                                          194          65.10
  Gender                                                     
   Male                                         284          95.30
   Female                                       14           4.70
  BMI, kg/m^2^ (mean ± SD)                      23.64±3.98   
  Education                                                  
   Illiterate and elementary school             212          71.14
   Higher than junior high school               86           28.86
  Hearing                                                    
   Good                                         195          65.44
   Poor                                         103          34.56
  Eyesight                                                   
   Good                                         116          38.93
   Poor                                         182          61.07
  Number of inhalers used                                    
   \<2                                          163          54.70
   ≥2                                           135          45.30
  Duration of inhaler use, months (mean ± SD)   9.91±13.68   
  Type of inhalers                                           
   MDI with spacer                              79           26.51
   Diskus^®^                                    20           6.71
   Turbuhaler^®^                                21           7.05
   Respimat^®^                                  223          74.83
   Breezhaler^®^                                100          33.56

**Note:** All data are presented as n (%) unless otherwise indicated.

**Abbreviations:** BMI, body mass index; MDI, metered-dose inhaler.

###### 

Characteristics of pass and misuse groups of patients using different inhalers

                                                MDI with spacer                                           Diskus^®^     Turbuhaler^®^   Respimat^®^   Breezhaler^®^                                                                                                                                                                                             
  --------------------------------------------- --------------------------------------------------------- ------------- --------------- ------------- -------------------------------------------------------- ------------- --------------------------------------------------------- -------------- --------------------------------------------------------- -------------
  Total                                         18 (22.78)                                                61 (77.22)    6 (30.00)       14 (70.00)    4 (19.05)                                                17 (80.95)    27 (12.11)                                                196 (87.89)    35 (35.00)                                                65 (65.00)
  Age, years (mean ± SD)                        69.39±8.49                                                72.21±9.53    68.17±7.68      70.71±11.52   68.50±11.24                                              70.54±11.21   69.85±8.35                                                72.21±8.74     71.20±8.27                                                73.46±80.84
   \<60                                         1 (5.56)                                                  5 (8.20)      1 (16.67)       3 (21.43)     1 (25.00)                                                2 (11.76)     3 (11.11)                                                 13 (6.63)      3 (8.57)                                                  4 (6.15)
   60--69                                       6 (33.33)                                                 15 (24.59)    3 (50.00)       1 (7.14)      1 (25.00)                                                5 (29.41)     9 (33.33)                                                 55 (28.06)     10 (28.57)                                                15 (23.08)
   ≥70                                          11 (61.11)                                                41 (67.21)    2 (33.33)       10 (71.43)    2 (50.00)                                                10 (58.82)    15 (55.56)                                                128 (65.31)    22 (62.86)                                                46 (70.77)
  Gender                                                                                                                                                                                                                                                                                                                                                        
   Male                                         17 (94.44)                                                56 (91.80)    6 (100.00)      13 (92.86)    4 (100.00)                                               16 (94.12)    26 (96.30)                                                191 (97.450)   34 (97.14)                                                63 (96.92)
   Female                                       1 (5.56)                                                  5 (8.20)      0 (0.00)        1 (7.14)      0 (0.00)                                                 1 (5.88)      1 (3.70)                                                  5 (2.55)       1 (2.86)                                                  2 (3.08)
  BMI (mean ± SD)                               22.96±4.27                                                23.88±4.36    26.91±4.14      23.55±3.74    23.85±3.70                                               24.59±4.13    23.69±3.92                                                23.33±3.84     23.67±4.23                                                23.65±3.72
  Education                                                                                                                                                                                                                                                                                                                                                     
   Illiterate and elementary school             13 (72.22)                                                43 (70.49)    2 (33.33)       8 (57.14)     1 (20.00)                                                12 (70.59)    21 (77.78)                                                144 (73.47)    26 (74.29)                                                48 (73.85)
   Higher than junior high school               5 (27.78)                                                 18 (29.51)    4 (66.67)       6 (42.86)     3 (60.00)                                                5 (29.41)     6 (22.22)                                                 52 (26.53)     9 (25.71)                                                 17 (26.15)
  Hearing                                                                                                                                                                                                                                                                                                                                                       
   Good                                         16 (88.89)[\*](#tfn4-copd-13-1309){ref-type="table-fn"}   31 (50.82)    5 (83.33)       9 (64.29)     4 (100.00)                                               13 (76.47)    22 (81.48)                                                130 (66.33)    25 (71.43)                                                45 (69.23)
   Poor                                         2 (11.11)                                                 30 (49.18)    1 (16.67)       5 (35.71)     0 (0.00)                                                 4 (23.53)     5 (18.52)                                                 66 (33.67)     10 (28.57)                                                20 (30.77)
  Eyesight                                                                                                                                                                                                                                                                                                                                                      
   Good                                         8 (44.44)                                                 23 (37.70)    3 (50.00)       4 (28.57)     2 (50.00)                                                8 (47.06)     12 (44.44)                                                74 (37.76)     15 (42.86)                                                25 (38.46)
   Poor                                         10 (55.56)                                                38 (62.30)    3 (50.00)       10 (71.43)    2 (50.00)                                                9 (52.94)     15 (55.56)                                                122 (62.24)    20 (57.14)                                                40 (61.54)
  Sedative agents                               2 (11.11)                                                 6 (9.84)      1 (16.67)       0 (0.00)      1 (25.00)                                                2 (11.76)     2 (7.41)                                                  26 (13.27)     4 (11.43)                                                 7 (10.77)
  Number of acute exacerbation (mean ± SD)      0.61±0.70                                                 0.43±0.83     0.17±0.41       0.21±0.43     0.25±0.50                                                0.18±0.39     0.30±0.47                                                 0.37±0.65      0.26±0.44[\*](#tfn4-copd-13-1309){ref-type="table-fn"}    0.58±0.63
  Number of inhalers used (mean ± SD)           1.72±0.75                                                 1.61±0.61     1.67±0.82       1.71±0.73     1.50±0.58                                                1.35±0.49     1.78±0.64                                                 1.63±0.55      1.94±0.54                                                 1.94±0.50
   \<2                                          8 (44.44)                                                 28 (45.90)    3 (50.00)       6 (42.86)     2 (50.00)                                                11 (64.71)    9 (33.33)                                                 80 (40.82)     6 (17.14)                                                 10 (15.38)
   ≥2                                           10 (55.56)                                                33 (54.10)    3 (50.00)       8 (57.14)     2 (50.00)                                                6 (35.29)     18 (66.67)                                                116 (59.18)    29 (82.86)                                                55 (84.62)
  Duration of inhaler use, months (mean ± SD)   7.44±9.81[\*](#tfn4-copd-13-1309){ref-type="table-fn"}    13.76±15.43   17.83±14.82     26.50±23.72   43.50±25.98                                              34.42±29.92   8.33±7.14                                                 9.75±8.40      2.27±1.78                                                 3.08±2.43
  Inhaler-related knowledge                                                                                                                                                                                                                                                                                                                                     
   Correct                                      11 (61.11)[\*](#tfn4-copd-13-1309){ref-type="table-fn"}   12 (19.67)    5 (83.33)       8 (57.14)     4 (100.0)[\*](#tfn4-copd-13-1309){ref-type="table-fn"}   4 (23.53)     19 (70.37)[\*](#tfn4-copd-13-1309){ref-type="table-fn"}   65 (33.16)     31 (88.57)[\*](#tfn4-copd-13-1309){ref-type="table-fn"}   37 (56.92)
   Incorrect                                    7 (38.89)                                                 49 (80.33)    1 (16.67)       6 (42.86)     0 (0.00)                                                 13 (76.47)    8 (29.63)                                                 131 (66.84)    4 (11.43)                                                 28 (43.08)

**Notes:** All data are presented as n (%) unless otherwise indicated. The number of acute exacerbation was investigated over the preceding 3 months.

There was a significant distribution or difference between the pass and misuse groups (*p*\<0.05).

**Abbreviations:** BMI, body mass index; MDI, metered-dose inhaler.

###### 

Misuse rates of patients performing each step for the five inhaler types

  Steps                                     MDI with spacer   Diskus^®^     Turbuhaler^®^   Respimat^®^   Breezhaler^®^
  ----------------------------------------- ----------------- ------------- --------------- ------------- ---------------
  Assembling the inhaler                                                                                  
   Yes                                      64 (81.01)        20 (100.00)   19 (98.48)      83 (37.22)    89 (89.00)
   No                                       15 (18.99)        0 (0.00)      2 (9.52)        140 (62.78)   11 (11.00)
  Holding the inhaler correctly                                                                           
   Yes                                      76 (96.20)        19 (95.00)    21 (100.00)     208 (93.27)   99 (99.00)
   No                                       3 (3.80)          1 (5.00)      0 (0.00)        15 (6.73)     1 (1.00)
  Breathing out fully                                                                                     
   Yes                                      27 (34.18)        6 (30.00)     4 (19.05)       70 (31.39)    42 (42.00)
   No                                       52 (68.82)        14 (70.00)    17 (80.95)      153 (68.61)   58 (58.00)
  Sealing lips around the mouthpiece                                                                      
   Yes                                      70 (88.61)        19 (95.00)    19 (90.48)      187 (83.86)   99 (99.00)
   No                                       9 (11.39)         1 (5.00)      2 (9.52)        36 (16.14)    1 (1.00)
  Pressing down the inhaler                                                                               
   Yes                                      78 (98.73)        --            --              218 (97.76)   100 (100.00)
   No                                       1 (1.27)          --            --              5 (2.24)      0 (0.00)
   Not applicable                           --                20 (100.00)   21 (100.00)     --            --
  Press for the number of puffs specified                                                                 
   Correct                                  67 (84.81)        --            --              200 (89.69)   --
   Incorrect                                12 (15.19)        --            --              23 (10.31)    --
   Not applicable                           --                20 (100.00)   21 (100.00)     --            100 (100.00)
  Inhalation timing                                                                                       
   Adequate                                 61 (77.22)        --            --              191 (85.65)   --
   Inadequate                               18 (22.78)        --            --              32 (14.35)    --
   Not applicable                           --                20 (100.00)   21 (100.00)     --            100 (100.00)
  Holding breath                                                                                          
   Yes                                      48 (60.76)        13 (65.00)    11 (52.38)      130 (58.30)   71 (71.00)
   No                                       31 (39.24)        7 (35.00)     10 (47.62)      93 (41.70)    29 (29.00)

**Notes:** All data are presented as the number (%) of patients undertaking the uncorrected step compared to the total number of observations. --, not applicable to the device.

**Abbreviation:** MDI, metered-dose inhaler.

###### 

Logistic regression analysis of the patient characteristics associated with inhaler misuse

                                                                          MDI with spacer      Diskus^®^            Turbuhaler^®^               Respimat^®^                  Breezhaler^®^                                                                                                          
  ----------------------------------------------------------------------- -------------------- -------------------- --------------------------- ---------------------------- --------------------------- --------------------------- -------------------- -------------------- -------------------- -----------------------
  Age                                                                     1.03 (0.98--1.09)    1.05 (0.96--1.15)    1.03 (0.93--1.13)           1.14 (0.03--48.21)           1.02 (0.92--1.12)           0.16 (\<0.01--\>999.9)      1.03 (0.99--1.08)    1.02 (0.96--1.08)    1.03 (0.98--1.08)    1.04 (0.97--1.11)
  Female (vs male)                                                        1.52 (0.17--13.89)   4.32 (0.20--92.88)   \>999.9 (\<0.01--\>999.9)   10.21 (\<0.01--\>999.9)      \>999.9 (\<0.01--\>999.9)   \<0.01 (\<0.01--\>999.9)    0.68 (0.08--6.06)    0.68 (0.06--7.43)    1.08 (0.09--12.33)   0.13 (\<0.01--128.95)
  BMI                                                                     1.05 (0.93--1.20)    1.05 (0.89--1.25)    0.79 (0.59--1.06)           0.26 (\<0.01--\>999.9)       1.05 (0.79--1.40)           12.63 (\<0.01--\>999.9)     0.98 (0.88--1.08)    0.99 (0.88--1.12)    1.00 (0.90--1.11)    1.02 (0.89--1.15)
  Educational level                                                                                                                                                                                                                                                                                 
   Higher than junior high school (vs illiterate and elementary school)   1.09 (0.34--3.50)    1.73 (0.29--10.17)   0.38 (0.05--2.77)           \>999.9 (\<0.01--\>999.9)    0.14 (0.01--1.68)           \<0.01 (\<0.01--\>999.9)    1.26 (0.48--3.30)    2.03 (0.70--6.02)    1.02 (0.40--2.62)    1.22 (0.35--4.27)
  Hearing                                                                                                                                                                                                                                                                                           
   Poor (vs good)                                                         7.74 (1.64--36.60)   9.85 (1.40--69.30)   2.78 (0.25--30.91)          \>999.9 (\<0.01--\>999.9)    \>999.9 (\<0.01--\>999.9)   \>999.9 (\<0.01--\>999.9)   2.23 (0.81--6.17)    1.55 (0.49--4.88)    1.11 (0.45--2.74)    0.78 (0.21--2.97)
  Eyesight                                                                                                                                                                                                                                                                                          
   Poor (vs good)                                                         1.32 (0.46--3.83)    0.66 (0.13--3.46)    2.50 (0.35--18.04)          \>999.9 (\<0.01--\>999.9)    1.13 (0.13--9.94)           \>999.9 (\<0.01--\>999.9)   1.32 (0.59--2.97)    1.30 (0.50--3.40)    1.20 (0.52--2.77)    0.90 (0.27--2.95)
  Sedative agents                                                         0.87 (0.16--4.75)    0.49 (0.07--3.69)    \<0.01 (\<0.01--\>999.9)    \<0.01 (\<0.01--\>999.9)     0.40 (0.03--5.96)           \<0.01 (\<0.01--\>999.9)    1.91 (0.43--8.55)    1.30 (0.27--6.28)    1.94 (0.25--3.44)    0.800 (0.15--4.21)
  Number of acute exacerbations                                           0.77 (0.42--1.41)    0.62 (0.26--1.48)    1.36 (0.11--16.58)          \>999.99 (\<0.01--\>999.9)   0.64 (0.05--8.51)           \<0.01 (\<0.01--\>999.9)    1.22 (0.59--2.52)    1.36 (0.55--3.38)    2.97 (1.27--6.85)    4.07 (1.50--11.08)
  Number of inhalers used \<2 (vs ≥2)                                     0.94 (0.33--2.71)    2.30 (0.51--10.32)   1.33 (0.20--9.08)           \>999.99 (\<0.01--\>999.9)   0.55 (0.06--4.91)           \>999.9 (\<0.01--\>999.9)   0.73 (0.31--1.70)    0.65 (0.25--1.68)    1.14 (0.38--3.44)    1.65 (0.37--7.43)
  Duration of inhaler use (months)                                        1.05 (0.99--1.11)    1.03 (0.96--1.11)    1.02 (0.97--1.08)           1.65 (0.15--18.44)           0.99 (0.95--1.03)           0.77 (0.04--15.88)          1.02 (0.97--1.08)    1.02 (0.96--1.08)    1.21 (0.96--1.51)    1.33 (0.99--1.78)
  Inhaler-related knowledge                                                                                                                                                                                                                                                                         
   Incorrect (vs correct)                                                 6.42 (2.06--20.04)   9.58 (2.14--42.80)   3.75 (0.34--41.08)          \>999.99 (\<0.01--\>999.9)   \>999.9 (\<0.01--\>999.9)   \>999.9 (\<0.01--\>999.9)   4.79 (1.99--11.51)   5.14 (2.07--12.76)   5.87 (1.86--18.55)   6.98 (1.95--25.08)

**Notes:** The number of acute exacerbation was investigated over the preceding 3 months. The association between the patient characteristics and misuse was calculated using a logistic regression model.

**Abbreviations:** BMI, body mass index; MDI, metered-dose inhaler; cOR, crude odds ratio; aOR, adjusted odds ratio; CI, confidence interval.
